RWM
NBIX icon

Rialto Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Rialto Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7K Buy
16
+7
+78% +$1.04K ﹤0.01% 1006
2026
Q1 		$1.19K Buy
9
+3
+50% +$398 ﹤0.01% 1045
2025
Q4 		$851 Buy
6
+1
+20% +$145 ﹤0.01% 1054
2025
Q3 		$702 Buy
5
+2
+67% +$271 ﹤0.01% 1074
2025
Q2 		$378 Buy
+3
New +$344 ﹤0.01% 1237

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rialto Wealth Management's NBIX Position: Q2 2026 in Review

Rialto Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 78% in Q2 2026, buying an estimated $1.04K and bringing the position to 16 shares worth $2.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

Rialto Wealth Management first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Rialto Wealth Management held 16 shares of Neurocrine Biosciences worth $2.7K as of Q2 2026.
  • Rialto Wealth Management bought 7 Neurocrine Biosciences shares in Q2 2026, an estimated $1.04K.
  • Neurocrine Biosciences made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1006 holding.
  • Rialto Wealth Management first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.